The American Journal of Pathology Instructions to Authors

Available online at http://ajp.amjpathol.org/authorinfo

The American Journal of Pathology, the official journal of the American Society for Investigative Pathology (ASIP) and published by Elsevier, Inc., seeks to publish high-quality original papers on the cellular and molecular biology of disease. The Editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.

Manuscript Categories. Regular Articles are categorized in the Table of Contents according to the following research topics: Animal Models; Biomarkers, Genomics, Proteomics, and Gene Regulation; Biophysical Imaging and Computational Biology; Cardiovascular, Pulmonary and Renal Pathology; Cell Injury, Repair, Aging, and Apoptosis; Epithelial and Mesenchymal Cell Biology; Gastrointestinal, Hepatobiliary and Pancreatic Pathology; Growth Factors, Cytokines, and Cell Cycle Molecules; Immunopathology and Infectious Diseases; Matrix Pathobiology; Metabolic, Endocrine, and Genitourinary Pathobiology; Molecular Pathogenesis of Genetic and Inherited Diseases; Musculoskeletal Pathology; Neurobiology; Stem Cells, Tissue Engineering, and Hematopoietic Elements; Tumorigenesis and Neoplastic Progression; and Vascular Biology, Atherosclerosis and Endothelium Biology. Not all topic areas will appear in each issue, as this is dependent on the content of original research accepted for publication. Upon acceptance, authors will be asked for their preference of topic category assignment; however, the Editors will make the final determination regarding topic category placement. There are no official limits to word count or figure number for Regular Articles; however, the Editors reserve the right to request reduction of text length or removal of data.

Short Communications are intended to provide a forum for the rapid publication of timely and significant findings, in brief. Manuscripts in this category should be concise but definitive, may be more descriptive and less mechanistic than Regular Articles, and must not exceed 12 double-spaced typed pages (excluding references and legends) and a maximum of 4 combined figures and tables; this limit is not to be circumvented by inclusion of excessive Supplemental Data. Categorization of manuscripts in this category is at the Editor's discretion

In addition to original research articles, the Journal publishes articles categorized as **Reviews**, **Mini-Reviews**, **Biological Perspectives**, **Commentaries**, **Guest Editorials**, and **Perspectives**. Authors who wish to publish a Review or Mini-Review should send their curriculum vitae along with an outline of the proposed article for prior approval by the Editor-in-Chief. **Reviews** have a maximum of 6,000 words, 100 references, and 4 tables or figures (one of which is mechanistic); **Mini-Reviews** have a maximum of 4,000 words, 50 references, and 2 tables or figures (one of which is mechanistic). **Biological Perspectives** are submitted by invitation only and provide streamlined, mechanistic insight into the current state of research in the discussed topic. **Commentaries** are submitted by invitation only and relate to a concurrently published manuscript. All invited papers are subject to the same review process as unsolicited articles. **Guest Editorials** and **Perspectives** are published by invitation only.

Review Process. The Editors perform an initial evaluation on all submissions to determine whether they believe the manuscript will achieve a sufficient priority score to warrant publication. Priority is determined by the Editors' assessment of the manuscript relative to other papers being considered. The aim is that expeditious treatment will enable authors to submit their manuscript elsewhere as soon as possible without suffering unnecessary delays. For manuscripts accepted for external review, the Editor-in-Chief assigns manuscripts to Associate Editors according to their expertise. The Associate Editor will solicit reviewers (typically, two to three external reviews are sought). Authors are encouraged to identify up to five potential

reviewers. Authors may also request that specific reviewers not be used due to prior collaborations, known conflicts of interest, or direct competition. The Editors will make every effort to respect requests that are well-founded; however, the Editors do have the authority to utilize such a reviewer if it is necessary for expert peer review. It is the practice of the Journal to conduct a blinded peer-review process. The peer-review process is kept completely confidential; it is considered a violation of this confidentiality for authors to identify or attempt to communicate directly with peer reviewers or Associate Editors regarding their manuscript. All editorial communications should be directed through the Editorial Office at ajp@asip.org. The reviewer comments and Associate Editor's recommendation are evaluated by the Editor-in-Chief for disposition and transmittal to the authors. Every effort is made to complete the review process within 30 days of the date received.

Review Decisions. Only a portion of manuscripts will be accepted for publication. A number of worthy manuscripts will be rejected based on priority. The Journal will advise authors whether the manuscript is accepted, acceptable with revisions, rejected but encourage resubmission (after major revision), or rejected. A manuscript may be returned to the authors without outside review if the Editors find it inappropriate for publication in this Journal. **Appeals** (rebuttals) to editorial decisions must be submitted within 60 days to be considered.

Journal Scientific Integrity Policy. The Journal has developed principles for defining proper conduct and scientific misconduct as well as procedures for handling such matters. General guidelines are described below; detailed information can be viewed at http://ajp.amjpathol.org/content/integrity. To report suspected misconduct relating to authors, reviewers, or Editors, send written complaint to the Editorial Office at The American Journal of Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or ajp@asip.org. Issues relating to staff conduct should be directed to the ASIP Executive Officer at American Society for Investigative Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or mesobel@asip.org.

Authors

Authorship. Authorship is defined as 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the manuscript or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3. When a group serves as a coauthor, the list of members (individuals or institutions) should be included in the Acknowledgements. When submitting a manuscript to the Journal, the corresponding author takes responsibility on behalf of all authors for the authorship, authenticity, and integrity of the research being reported. Any change made to the list of authors (addition, removal, change in order) after manuscript acceptance requires consent of all authors and editorial approval.

Author Conduct. Authors should take special care that manuscripts submitted to the Journal are prepared in accordance with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see http://www.icmje.org); in particular the ethical considerations regarding authorship, conflicts of interest, redundant publication, and treatment and confidentiality of research subjects should be carefully adhered to. Additionally, the Journal takes great care to secure the confidentiality and integrity of the peer-review process; it is considered a violation of this confidentiality for authors to identify or attempt to communicate directly with peer reviewers or Associate Editors regarding their manuscript. All editorial communications should be directed through the Editorial Office at app@asip.org. The Editors will consider any deliberate ethical violation in either the reported research or the manuscript preparation and review to be actionable misconduct, the potential results of which may be manuscript rejection or public article retraction, reporting of conduct to the authors' governing institutions, and/or the denial to consider any future submissions to the Journal. Willful misconduct does not include incidents of honest misjudgment or inadvertent error. Detailed information regarding possible misconduct can be found in the Journal Scientific Integrity Policy at http://ajp.amjpathol.org/content/integrity.

Manuscript Submission. Manuscripts should be submitted online via the Rapid Review system (http://www.rapidreview.com/ASIP2/ CALogon.jsp). Detailed instructions on preparing and submitting files can be found on the author submission website at the above URL. Authors having difficulty submitting files online should complete the online submission form on Rapid Review to receive the assigned manuscript number. With the manuscript number clearly noted, electronic files (manuscript text, figures, tables, and supplemental data) should be emailed to the Editorial Office at ajp@asip.org or sent on disk by mail to: The American Journal of Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993. The cover letter must state any conflicts of interest (both financial and personal), affirm that the manuscript has not been published previously and is not being considered concurrently by another publication, and affirm that all authors and acknowledged contributors have read and approved the manuscript. Submissions will be ineligible for review if previously published in any form (print or online) other than as an abstract. This includes any public posting of raw manuscripts or prereviewed material.

A non-refundable manuscript processing fee of US\$50 is required with submission. This fee should be paid electronically at the time of submission. Corresponding authors of submitted manuscripts who are current, dues-paying Regular or Next-Century Members of ASIP at the time of submission will receive free submission (see http://www.asip.org/apply/categories.cfm for ASIP membership information). Manuscripts arising from research in developing countries may be eligible for waiver of the submission fee only if all authors are located in a qualifying country (waiver must be applied for at time of submission; for a list of eligible countries, see Group A and Group B countries at http://www.who.int/hinari/eligibility/en). Otherwise, manuscript submission fees will not be waived.

Manuscript Preparation. Manuscripts should be prepared in the style of the Journal and in accordance with The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see http://www.icmje.org). The preferred file format for text is MS Word. Standard abbreviations can be found in the CSE Style Manual: Scientific Style and Format (8th ed., 2014). All pages of the manuscript should be double-spaced and numbered (including references, tables and figure legends); line numbers should also be included to assist reviewers in making comments. Other formatting specifications (eg, font size and type, margin settings, etc) are left to the authors' discretion, as papers accepted for publication will be reformatted according to the print specifications of the Journal. Manuscripts not prepared in accordance with the submission guidelines detailed below may be returned to the authors. Authors are encouraged to include a list of nonstandard abbreviations to aid reviewers; however, the Journal does not publish abbreviations or keywords as part of the final article. In addition, authors should be ready to comply with Editors' requests for copies of any similar works in preparation, copies of cited manuscripts that are submitted or in press, and/or supporting manuscript data (eg, data not shown but summarized in the manuscript) that may aid the review process. The Editorial Office screens content for high similarities between accepted manuscript text and previously published content (PubMed-indexed and online-only material) by using the online plagiarism detection tool iThenticate (http://www.ithenticate.com/about).

Title Page(s). The title page(s) must include a concise title accurately reflecting the findings of the work; full names (not initials) of all authors; department, institution and address where the research was performed; number of text pages, tables, and figures; a short running head (40 characters or less); grant numbers and sources of support (including departmental or institutional funding when no extramural funding was received); and name, address, phone, fax, and email of the corresponding author(s). If an author changes employment after the study was performed, the new affiliation information for that author should be included as a footnote. Any relationships held by the author or an immediate family member (eg, employment, consultancies, board membership, stock ownership, funding, honoraria, expert testimony, patents or royalties, travel reimbursements, industry-supplied free reagents, etc) with any

organization or entity having a direct financial or personal interest in the subject matter or materials discussed in the article should also be clearly stated.

Abstract. An abstract of 220 words or less should be prepared on a separate page and should be intelligible to the general reader without reference to the text. The abstract should clearly summarize the background, methodology, results, and significance of the study. Abbreviations and citations should be avoided.

Text. The remaining sections of the text, which should include Introduction, Materials and Methods, Results, Discussion, and Acknowledgments (in this order), need not begin on new pages. Commonly-abbreviated terms should be spelled out in their first occurrence and then may be referenced in abbreviation through the remainder of the manuscript. The Journal requires the use of official gene and protein symbols, to facilitate standardization of scientific communication. Consult the Human Genome Organisation Gene Nomenclature Committee website (http://www.genenames.org) for human gene names and symbols, the Mouse Genome Informatics Database (http://www.informatics.jax.org/mgihome/nomen) for mouse gene names and symbols, and UniProt (http://www.uniprot.org) for protein names and symbols. For a complete list of other approved nomenclature organizations (eg, bacteria, viruses), please contact the Editorial Office.

For Materials and Methods, authors should describe experimental and statistical methods in enough detail that other researchers can replicate results and evaluate claims. The Journal is a signatory of the NIH Principles and Guidelines for Reporting Preclinical Research (see http://www.nih.gov/about/reporting-preclinical-research.htm). Inclusion of method or reagent details as supplementary material is not acceptable. In addition, linking to protocols online is not permissible as there is no guarantee that the information will remain unchanged and accessible in perpetuity. The sequences of oligonucleotides, if not previously published, should be provided. Novel DNA or protein sequences should be deposited to an appropriate database (eg, Genbank, EMBL, SWISS-PROT), with the accession numbers included in the manuscript. When providing supplier information for materials sources, company name and location (city and state, or city and country) should be provided. When describing reagents such as antibodies, cell lines, animal strains, bacteria, and viruses, authors should include the source, characteristics, dilutions, strain, species, sex, authentication, etc. as necessary for repetition of the experiments. Website references to company information are not permitted. All novel materials and the procedures to prepare them should be described in sufficient detail to allow their reproduction (eg, DNA constructs, analytical software). Materials that are approved for investigational-use only should be clearly indicated.

Methods should state whether sample size was determined statistically prior to experimentation, whether samples were randomized (and how), whether data acquisition was blinded (particularly for subjective scoring methodologies), and what criteria were used to include/exclude data points or subjects. Experimental procedures should include the number of replicates performed and the number of samples in each experimental condition. Special care should be taken to assure that statistical methods are appropriate, with clearly defined statements of the statistical test(s) used, sample size, and measures reported (eg, mean, median, SD, SEM, confidence intervals). The Editors will seek the assistance of statistical experts as necessary to fully evaluate the validity of statistical methods reported.

Publication in the Journal implies that the authors agree, upon reasonable request, to share any materials or data that are integral to the results presented in the article, including whatever would be necessary for a skilled investigator to verify or replicate the claims. This may include original software code used in the data analysis. Agreement to share reagents or software code does not preclude the authors from implementing a Data Use Agreement. Authors must disclose upon submission any restrictions on the availability of materials or information, such as for patented or dual-purpose materials.

Reporting guidelines for specific study designs (eg, randomized controlled trials) can be found online via the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network (see http://www.equator-network.org/reporting-guidelines). Authors must affirm that the research protocol was approved by the appropriate

Download English Version:

https://daneshyari.com/en/article/5932295

Download Persian Version:

https://daneshyari.com/article/5932295

<u>Daneshyari.com</u>